Novartis announced late-breaking data from the CLEAR study that demonstrated Cosentyx (secukinumab) was superior to Stelara (ustekinumab) in reaching near clear skin on the PASI 90 in significantly more moderate to severe psoriasis patients at Week 52. The findings were presented at the American Academy of Dermatology’s 74th Annual Meeting.
In the CLEAR (Comparison to assess Long-term Efficacy, sAfety and toleRability of secukinumab vs. ustekinumab) study, treatment with Cosentyx resulted in Psoriasis Area Severity Index (PASI) 90 response of 80.1% vs. 59.0% in the Stelara treatment group at Week 16 (P<0.0001). At Week 52, treatment with Cosentyx remained superior to Stelara in achieving PASI 90 (76.2% vs. 60.6%; P<0.0001). The study also showed half of the patients in the Cosentyx treatment group achieved PASI 75 at Week 4 vs. 20.6% of patients in the Stelara treatment group (P<0.0001).
A separate analysis showed a greater percentage of Cosentyx patients achieved completely clear skin (PASI 100) vs. Stelara patients at Week 52 (45.9% vs. 35.8%; P=0.0103).Also, treatment with Cosentyx showed significantly greater Dermatology Life Quality Index (DLQI) 0/1 responses vs. Stelara (71.6% vs. 59.2%; P=0.0008).
Cosentyx, a interleukin-17A antagonist, is approved for use in adults with moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is available as 150mg/mL single-use Sensoready pens, single-use prefilled syringes, and single-use vials.
For more information call (800) 693-9993 or visit Cosentyx.com.